ArticleBriefings in bioinformatics2025
Classifier-driven generative adversarial networks for enhanced antimicrobial peptide design.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- tsAMP: a strain-level antimicrobial peptide identification framework based on large language models and pathogen genomic variation.Frontiers in microbiology · 2026Article
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The development of antimicrobial peptides (AMPs) presents a promising approach to addressing antibiotic-resistant pathogens. Computational methods, such as Feedback Generative Adversarial Networks (FBGANs), have demonstrated strong performance in optimizing AMP design. FBGAN operates as a classifier-guided Generative Adversarial Network (GAN), refining training data by replacing them with the classifier's most accurate predictions based on a predefined threshold. However, this method may introduce bias and constrain the diversity and quality of the generated peptides. To address these limitations, we propose a novel classifier-driven GAN (cdGAN) framework that seamlessly integrates classifier predictions into the generative model's loss function. This enables an adaptive, end-to-end learning process that enhances AMP generation without requiring explicit data modifications. By embedding classifier guidance within the loss computation, cdGAN dynamically optimizes both peptide diversity and functionality. Comparative studies indicate that cdGAN outperforms conventional guided-GAN architectures, such as Conditional GANs and Auxiliary Classifier GANs, while achieving performance comparable to or exceeding established AMP design methods. Additionally, cdGAN's flexible architecture allows for the simultaneous optimization of multiple peptide attributes. To demonstrate this capability, we introduce a multi-task classifier based on the Evolutionary Scale Modeling 2 (ESM2) model, enabling cdGAN to assess both antimicrobial activity and peptide structural properties in parallel. This enhancement improves the likelihood of generating viable therapeutic candidates with enhanced antimicrobial effectiveness and reduced toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.